Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 5-Fluorouracil (5-FU)
5-fluorouracil · 1 trial · 1 indication
The incidence of DLTs assessed during the first cycle (21 days).
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 5-fluorouracil | DRUG | 5- fluorouracil is given as 4000 mg/m\^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. |
| cisplatin | DRUG | Cisplatin is given 80 mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. |
| sunitinib malate | DRUG | sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. |
Inclusion Criteria: * confirmed diagnosis of stomach cancer * advanced stomach cancer stage IV * adequate blood chemistry, blood counts and kidney function * willing to participate to study requirements and to sign an informed consent document Exclusion Criteria: * prior chemotherapy for stomach ...
5 fluorouracil, also known as 5-Fluorouracil (5-FU), is an oncology small molecule being studied for metastatic colorectal cancer and stomach neoplasms. It is part of combination chemotherapy regimens, such as FOLFIRI, in clinical trials for these advanced cancers.
5 fluorouracil is a small molecule antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis in rapidly dividing cancer cells. It is used in combination regimens for metastatic colorectal cancer and stomach neoplasms.
5 fluorouracil is being developed by Pfizer, Inc. (NYSE: PFE). The company sponsors clinical trials evaluating the drug in combination with other agents for metastatic colorectal cancer and stomach neoplasms.
5 fluorouracil is in Phase 3 clinical development for metastatic colorectal cancer. It is also being studied in a Phase 1 trial for stomach neoplasms. The drug is investigational and not yet approved for these indications.
5 fluorouracil is being studied in NCT00457691, a completed Phase 3 trial of FOLFIRI chemotherapy with or without sunitinib in 768 patients with metastatic colorectal cancer, and NCT00555672, a completed Phase 1 trial of sunitinib with cisplatin and 5-fluorouracil in 34 patients with advanced gastric cancer.
Yes, 5 fluorouracil is the same as 5-Fluorouracil (5-FU). It is also referred to as 5-Fluorouracil. These names are used interchangeably in clinical research and medical literature.